Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Hicham Skali, M.D.

Co-Author

This page shows the publications co-authored by Hicham Skali and Scott Solomon.
Connection Strength

8.427
  1. Response to Letter Regarding Article, “Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study”. Circ Heart Fail. 2015 Sep; 8(5):1010.
    View in: PubMed
    Score: 0.658
  2. Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study. Circ Heart Fail. 2015 May; 8(3):448-54.
    View in: PubMed
    Score: 0.637
  3. Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. Eur J Heart Fail. 2014 May; 16(5):560-5.
    View in: PubMed
    Score: 0.593
  4. Reducing infarct size with EPO in patients with ST-segment elevation myocardial infarction. Am J Kidney Dis. 2011 Dec; 58(6):876-8.
    View in: PubMed
    Score: 0.502
  5. Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. Am Heart J. 2011 Sep; 162(3):548-54.
    View in: PubMed
    Score: 0.497
  6. Variable impact of combining fatal and nonfatal end points in heart failure trials. Circulation. 2006 Nov 21; 114(21):2298-303.
    View in: PubMed
    Score: 0.358
  7. Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study. JAMA Cardiol. 2018 03 01; 3(3):200-206.
    View in: PubMed
    Score: 0.196
  8. Kidney Disease Measures and Left Ventricular Structure and Function: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2017 Sep 22; 6(9).
    View in: PubMed
    Score: 0.190
  9. Soluble ST2 and Risk of Arrhythmias, Heart Failure, or Death in Patients with Mildly Symptomatic Heart Failure: Results from MADIT-CRT. J Cardiovasc Transl Res. 2016 12; 9(5-6):421-428.
    View in: PubMed
    Score: 0.178
  10. Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 2016 May; 39(5):677-85.
    View in: PubMed
    Score: 0.169
  11. Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2015 Mar; 17(3):301-12.
    View in: PubMed
    Score: 0.158
  12. Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. Eur Heart J. 2015 Mar 14; 36(11):669-75.
    View in: PubMed
    Score: 0.155
  13. Heart failure risk across the spectrum of ankle-brachial index: the ARIC study (Atherosclerosis Risk In Communities). JACC Heart Fail. 2014 Oct; 2(5):447-54.
    View in: PubMed
    Score: 0.154
  14. Temporal trends in the population attributable risk for cardiovascular disease: the Atherosclerosis Risk in Communities Study. Circulation. 2014 Sep 02; 130(10):820-8.
    View in: PubMed
    Score: 0.153
  15. Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. BMJ Open Diabetes Res Care. 2014; 2(1):e000011.
    View in: PubMed
    Score: 0.149
  16. Rationale and design of a multicenter echocardiographic study to assess the relationship between cardiac structure and function and heart failure risk in a biracial cohort of community-dwelling elderly persons: the Atherosclerosis Risk in Communities study. Circ Cardiovasc Imaging. 2014 Jan; 7(1):173-81.
    View in: PubMed
    Score: 0.145
  17. Differential influence of distinct components of increased blood pressure on cardiovascular outcomes: from the atherosclerosis risk in communities study. Hypertension. 2013 Sep; 62(3):492-8.
    View in: PubMed
    Score: 0.142
  18. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011 Dec 20; 124(25):2903-8.
    View in: PubMed
    Score: 0.127
  19. Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. Eur J Heart Fail. 2012 Feb; 14(2):185-92.
    View in: PubMed
    Score: 0.125
  20. Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. Am Heart J. 2011 Oct; 162(4):685-91.
    View in: PubMed
    Score: 0.125
  21. Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. Am Heart J. 2011 Jun; 161(6):1156-62.
    View in: PubMed
    Score: 0.122
  22. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011 May; 32(10):1227-34.
    View in: PubMed
    Score: 0.120
  23. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J. 2010 May; 31(9):1088-97.
    View in: PubMed
    Score: 0.111
  24. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. JACC Cardiovasc Imaging. 2008 Sep; 1(5):582-91.
    View in: PubMed
    Score: 0.101
  25. Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study). Am J Cardiol. 2008 Mar 01; 101(5):607-12.
    View in: PubMed
    Score: 0.098
  26. High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Am Heart J. 2008 Apr; 155(4):706-11.
    View in: PubMed
    Score: 0.097
  27. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007 Sep 25; 116(13):1482-7.
    View in: PubMed
    Score: 0.094
  28. Two-dimensional assessment of right ventricular function: an echocardiographic-MRI correlative study. Echocardiography. 2007 May; 24(5):452-6.
    View in: PubMed
    Score: 0.092
  29. Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. Eur Heart J. 2007 Feb; 28(3):326-33.
    View in: PubMed
    Score: 0.091
  30. Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study. J Am Soc Echocardiogr. 2006 Dec; 19(12):1462-5.
    View in: PubMed
    Score: 0.090
  31. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol. 2006 Oct; 17(10):2886-91.
    View in: PubMed
    Score: 0.088
  32. Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction. J Am Coll Cardiol. 2006 Apr 18; 47(8):1725-7.
    View in: PubMed
    Score: 0.086
  33. Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. Heart Rhythm. 2006 Mar; 3(3):313-6.
    View in: PubMed
    Score: 0.085
  34. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005 Dec 13; 112(24):3738-44.
    View in: PubMed
    Score: 0.084
  35. Prognostic use of echocardiography 1 year after a myocardial infarction. Am Heart J. 2005 Oct; 150(4):743-9.
    View in: PubMed
    Score: 0.083
  36. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. Am Heart J. 2005 Aug; 150(2):257-62.
    View in: PubMed
    Score: 0.082
  37. Prognostic significance of troponin elevation and right ventricular enlargement in acute pulmonary embolism. Am J Cardiol. 2005 Jul 15; 96(2):303-5.
    View in: PubMed
    Score: 0.082
  38. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation. 2005 Jun 28; 111(25):3411-9.
    View in: PubMed
    Score: 0.081
  39. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation. 2004 Dec 14; 110(24):3667-73.
    View in: PubMed
    Score: 0.078
  40. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2004 Oct 12; 110(15):2180-3.
    View in: PubMed
    Score: 0.077
  41. Alcohol consumption and prognosis in patients with left ventricular systolic dysfunction after a myocardial infarction. J Am Coll Cardiol. 2004 Jun 02; 43(11):2015-21.
    View in: PubMed
    Score: 0.075
  42. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation. 2002 Sep 03; 106(10):1251-5.
    View in: PubMed
    Score: 0.067
  43. Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life. JAMA Cardiol. 2021 May 01; 6(5):509-520.
    View in: PubMed
    Score: 0.061
  44. High-Sensitivity Cardiac Troponin, Natriuretic Peptide, and Long-Term Risk of Acute Kidney Injury: The Atherosclerosis Risk in Communities (ARIC) Study. Clin Chem. 2021 01 08; 67(1):298-307.
    View in: PubMed
    Score: 0.060
  45. Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis. PLoS Med. 2020 10; 17(10):e1003361.
    View in: PubMed
    Score: 0.059
  46. Mid- to Late-Life Time-Averaged Cumulative Blood Pressure and Late-Life Cardiac Structure, Function, and Heart Failure. Hypertension. 2020 09; 76(3):808-818.
    View in: PubMed
    Score: 0.057
  47. Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. Eur J Heart Fail. 2020 07; 22(7):1133-1143.
    View in: PubMed
    Score: 0.056
  48. Coronary Microvascular Dysfunction, Left Ventricular Remodeling, and Clinical Outcomes in Patients With Chronic Kidney Impairment. Circulation. 2020 01 07; 141(1):21-33.
    View in: PubMed
    Score: 0.055
  49. Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults. JAMA Cardiol. 2019 10 01; 4(10):997-1006.
    View in: PubMed
    Score: 0.055
  50. Association of Undifferentiated Dyspnea in Late Life With Cardiovascular and Noncardiovascular Dysfunction: A Cross-sectional Analysis From the ARIC Study. JAMA Netw Open. 2019 06 05; 2(6):e195321.
    View in: PubMed
    Score: 0.053
  51. Widening Racial Differences in Risks for Coronary Heart Disease. Circulation. 2018 03 13; 137(11):1195-1197.
    View in: PubMed
    Score: 0.049
  52. Cardiovascular Dysfunction and Frailty Among Older Adults in the Community: The ARIC Study. J Gerontol A Biol Sci Med Sci. 2017 Jul 01; 72(7):958-964.
    View in: PubMed
    Score: 0.047
  53. Racial Disparities in Risks of Stroke. N Engl J Med. 2017 05 25; 376(21):2089-2090.
    View in: PubMed
    Score: 0.046
  54. Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. Eur Stroke J. 2016 Jun; 1(2):93-100.
    View in: PubMed
    Score: 0.043
  55. Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. Eur Heart J. 2016 Feb 01; 37(5):466-72.
    View in: PubMed
    Score: 0.042
  56. Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia--the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT). J Hum Hypertens. 2016 Jan; 30(1):46-52.
    View in: PubMed
    Score: 0.040
  57. Association of high-sensitivity cardiac troponin T and natriuretic peptide with incident ESRD: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis. 2015 Apr; 65(4):550-8.
    View in: PubMed
    Score: 0.039
  58. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014 Aug 01; 32(22):2380-5.
    View in: PubMed
    Score: 0.038
  59. Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device. J Heart Lung Transplant. 2014 Apr; 33(4):372-81.
    View in: PubMed
    Score: 0.037
  60. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol. 2012 May 15; 59(20):1785-95.
    View in: PubMed
    Score: 0.033
  61. Mortality rates in trials of subjects with type 2 diabetes. J Am Heart Assoc. 2012 Feb; 1(1):8-15.
    View in: PubMed
    Score: 0.032
  62. Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation. 2010 Aug 10; 122(6):597-602.
    View in: PubMed
    Score: 0.029
  63. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007 Aug 07; 116(6):627-36.
    View in: PubMed
    Score: 0.023
  64. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. Heart Rhythm. 2007 Mar; 4(3):308-13.
    View in: PubMed
    Score: 0.022
  65. Risk assessment in patients with depressed left ventricular function after myocardial infarction using the myocardial performance index--Survival and Ventricular Enlargement (SAVE) experience. J Am Soc Echocardiogr. 2006 Jan; 19(1):28-33.
    View in: PubMed
    Score: 0.021
  66. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation. 2004 Sep 21; 110(12):1572-8.
    View in: PubMed
    Score: 0.019
  67. Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol. 2002 May 01; 39(9):1450-5.
    View in: PubMed
    Score: 0.016
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.